ES2173433T3 - Procedimiento para la cristalizacion de losartan. - Google Patents

Procedimiento para la cristalizacion de losartan.

Info

Publication number
ES2173433T3
ES2173433T3 ES97913800T ES97913800T ES2173433T3 ES 2173433 T3 ES2173433 T3 ES 2173433T3 ES 97913800 T ES97913800 T ES 97913800T ES 97913800 T ES97913800 T ES 97913800T ES 2173433 T3 ES2173433 T3 ES 2173433T3
Authority
ES
Spain
Prior art keywords
losartan
procedure
crystallization
potassium
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97913800T
Other languages
English (en)
Inventor
Patrick Breen
Erik A Dienemann
Albert D Epstein
Karen A Larson
Michael T Kennedy
Hari Mahadevan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625804.1A external-priority patent/GB9625804D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2173433T3 publication Critical patent/ES2173433T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

EL POTASIO DE LOSARTAN ES UN ANTAGONISTA DE LA ANGIOTENSINA II QUE SE UTILIZA EN EL TRATAMIENTO DE LA HIPERTENSION Y DE LA INSUFICIENCIA CARDIACA GLOBAL (I). ESTA INVENCION SE REFIERE AL PROCEDIMIENTO DE CRISTALIZACION CONTROLADA DEL POTASIO DE LOSARTAN, EN EL CUAL SE UTILIZA UNA ADICION DE ANTIDISOLVENTE COMBINADA CON UNA SIEMBRA MASIVA DE FORMA QUE SE OBTENGA LA MORFOLOGIA DE CRISTAL DESEADA Y PROPIEDADES FISICAS GENERALES NECESARIAS PARA UNA FORMULACION SATISFACTORIA.
ES97913800T 1996-10-29 1997-10-24 Procedimiento para la cristalizacion de losartan. Expired - Lifetime ES2173433T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2932696P 1996-10-29 1996-10-29
GBGB9625804.1A GB9625804D0 (en) 1996-12-12 1996-12-12 Process for the crystallization of losartan

Publications (1)

Publication Number Publication Date
ES2173433T3 true ES2173433T3 (es) 2002-10-16

Family

ID=26310606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97913800T Expired - Lifetime ES2173433T3 (es) 1996-10-29 1997-10-24 Procedimiento para la cristalizacion de losartan.

Country Status (18)

Country Link
US (1) US5859258A (es)
EP (1) EP0937068B1 (es)
JP (1) JP3249827B2 (es)
CN (1) CN1101393C (es)
AR (1) AR010256A1 (es)
AT (1) ATE214388T1 (es)
AU (1) AU5089898A (es)
BR (1) BR9712390A (es)
CZ (1) CZ291672B6 (es)
DE (1) DE69711068T2 (es)
DK (1) DK0937068T3 (es)
EA (1) EA001046B1 (es)
ES (1) ES2173433T3 (es)
HR (1) HRP970565B1 (es)
PT (1) PT937068E (es)
SK (1) SK282875B6 (es)
TW (1) TW411338B (es)
WO (1) WO1998018787A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
JP2002080354A (ja) * 2000-09-05 2002-03-19 Kao Corp 血圧降下剤組成物
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
WO2002094816A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited Process for the crystallization of losartan potassium
AU2002334987A1 (en) * 2001-10-15 2003-04-28 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
SI1474417T1 (sl) 2002-04-29 2006-08-31 Teva Pharma Postopek za pripravo lozartana in kalijevega lozartana
US20040097568A1 (en) * 2002-07-29 2004-05-20 Dr. Reddy's Laboratories Limited Crystalline form of losartan potassium
ES2290518T3 (es) * 2002-10-17 2008-02-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de losartan potasico con fluidez mejorada.
US20060241305A1 (en) * 2002-10-31 2006-10-26 Yatendra Kumar Amorphous form of losartan potassium
SI1589966T1 (sl) * 2003-01-30 2011-06-30 Lek Pharmaceuticals D.D. Postopek čiščenja losartana
WO2004076442A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Polymorphs of losartan
US7345071B2 (en) 2003-05-07 2008-03-18 Ipca Laboratories Limited Process for the synthesis of Losartan potassium
ITMI20032472A1 (it) * 2003-12-16 2005-06-17 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procedimento per la preparazione di losartan potassio cristallino
WO2005066158A2 (en) * 2004-01-06 2005-07-21 Ipca Laboratories Limited An improved process for the synthesis of losartan potassium
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
RU2384346C2 (ru) * 2004-06-23 2010-03-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
ITMI20050551A1 (it) * 2005-04-01 2006-10-02 Dipharma Spa Forma cristallina alfa di losartan potassio
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5130439A (en) * 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5310928A (en) * 1991-11-18 1994-05-10 E. I. Du Pont De Nemours And Company Process for preparing biphenyltetrazole compounds
US5206374A (en) * 1991-11-18 1993-04-27 E. I. Du Pont De Nemours And Company Process for preparing tetrazolylphenylboronic acid intermediates
DK0643704T3 (da) 1991-11-18 2004-01-19 Merck & Co Inc Tetrazolylphenylboronsyremellemprodukter til syntese af All-receptor antagonister
AU685898B2 (en) * 1993-12-23 1998-01-29 Du Pont Merck Pharmaceutical Company, The Polymorphs of losartan and the process for the preparation of form II of losartan

Also Published As

Publication number Publication date
JP2000504343A (ja) 2000-04-11
SK282875B6 (sk) 2003-01-09
EP0937068B1 (en) 2002-03-13
DK0937068T3 (da) 2002-05-21
WO1998018787A1 (en) 1998-05-07
BR9712390A (pt) 1999-08-31
CZ291672B6 (cs) 2003-04-16
AU5089898A (en) 1998-05-22
US5859258A (en) 1999-01-12
DE69711068T2 (de) 2002-09-12
HRP970565B1 (en) 2003-02-28
EA001046B1 (ru) 2000-08-28
CN1101393C (zh) 2003-02-12
AR010256A1 (es) 2000-06-07
PT937068E (pt) 2002-07-31
CN1241186A (zh) 2000-01-12
DE69711068D1 (de) 2002-04-18
TW411338B (en) 2000-11-11
EP0937068A1 (en) 1999-08-25
EA199900427A1 (ru) 1999-10-28
ATE214388T1 (de) 2002-03-15
SK57099A3 (en) 2000-02-14
JP3249827B2 (ja) 2002-01-21
HRP970565A2 (en) 1998-08-31
CZ151599A3 (cs) 1999-10-13

Similar Documents

Publication Publication Date Title
ES2173433T3 (es) Procedimiento para la cristalizacion de losartan.
PA8453501A1 (es) Derivados dipeptidicos
PA8620501A1 (es) Compuestos utiles en terapia
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
UY27711A1 (es) Compuestos útiles en terapia
UY26689A1 (es) Activadores de glucocinasa que contienen hidantoina
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20010062L (no) Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister
NO20055253L (no) Behandling av autoimmun sykdom i en pasient med utilstrekkelig respons pa en TNF-alfa-inhibitor
CR7074A (es) Derivados de mercaptoacetylamida y proceso para su preparacion y uso
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
EA202191152A1 (ru) Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
ES2060274T3 (es) Bloqueadores de receptores de angiotensina ii para el tratamiento de la hipertrofia cardiaca.
TW200507855A (en) Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren
ES2169763T3 (es) Derivados de pirimidinona.
DE60323645D1 (de) Duschvorrichtung mit bräunungsvorrichtung
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol
AR043395A1 (es) Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
ES2133390T3 (es) Derivados de triazolopirimidinas antagonistas de los receptores de la angiotensina ii.
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
ATE464904T1 (de) Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 937068

Country of ref document: ES